Senté, Inc. announces that it has closed its Series-B financing, raising $2.1 million from a combination of new and existing biotechnology investors. Proceeds from the financing will help Senté, Inc. expand commercial operations, scale development capabilities, and add additional line extensions to its portfolio of differentiated medical grade skin care products.
New Advances in Treating Hyperpigmentation
This past decade has seen an enormous surge in popularity of skin brightening products formulated specifically to treat hyperpigmentation and…


0 Comments